MB comment: This latest definitive study on the pertussis vaccine (DTaP) finds that immunity declines 42% per year after the fifth dose. In other words, scientists admit this vaccine is a failure.

For perspective, the current acellular pertussis vaccine (the aP in DTaP) replaced the whole cell vaccine in the 1990′s because the whole cell vaccine had ‘severe reactions such as convulsions (1 case per 1750 doses administered, according to a report by the Centers for Disease Control and Prevention [CDC]); rarely, acute encephalopathy (0 – 10.5 cases per 1 million doses administered, according to the CDC); and, some conclude, lasting brain damage.’ (source Medscape).

In other words, the current pertussis vaccine that is hyped and pushed incessantly by public health officials is not only a failure, it is dangerous and harmful.

But in the Alice in Wonderland world of vaccines, the next recommendation of CDC, public health officials and doctors will surely be MORE DOSES of this pathetic defective vaccine.

Medscape quotes a doctor who works for vaccine manufacturers (Michael Pichichero, MD, professor in pediatrics, University of Rochester Medical Center, New York) ‘Due to the vaccine practices of too many parents in California and the well-intentioned but misguided cooperation by healthcare providers, it may also be that the California pertussis outbreaks are due in part also to the lack of sufficient herd immunity to provide population protection’

The medical system has the gall to blame those who refuse their dangerous and defective vaccines for the failure of those same vaccines in those who take them.

If DTaP was a product like a baby stroller, it would be withdrawn from the market for being dangerous and useless.

Wake up people, buggy-whip vaccine technology is a threat to your health.

Background

In the United States, children receive five doses of diphtheria, tetanus, and acellular pertussis (DTaP) vaccine before 7 years of age. The duration of protection after five doses of DTaP is unknown.

Methods

We assessed the risk of pertussis in children in California relative to the time since the fifth dose of DTaP from 2006 to 2011. This period included a large outbreak in 2010. We conducted a case–control study involving members of Kaiser Permanente Northern California who were vaccinated with DTaP at 47 to 84 months of age. We compared children with pertussis confirmed by a positive polymerase-chain-reaction (PCR) assay with two sets of controls: those who were PCR-negative for pertussis and closely matched controls from the general population of health-plan members. We used logistic regression to examine the risk of pertussis in relation to the duration of time since the fifth DTaP dose. Children who received whole-cell pertussis vaccine during infancy or who received any pertussis-containing vaccine after their fifth dose of DTaP were excluded.

Results

We compared 277 children, 4 to 12 years of age, who were PCR-positive for pertussis with 3318 PCR-negative controls and 6086 matched controls. PCR-positive children were more likely to have received the fifth DTaP dose earlier than PCR-negative controls (P<0.001) or matched controls (P=0.005). Comparison with PCR-negative controls yielded an odds ratio of 1.42 (95% confidence interval, 1.21 to 1.66), indicating that after the fifth dose of DTaP, the odds of acquiring pertussis increased by an average of 42% per year.

Conclusions

Protection against pertussis waned during the 5 years after the fifth dose of DTaP. (Funded by Kaiser Permanente).

Drs. Klein and Baxter report receiving grant support to their institution from Sanofi Pasteur, GlaxoSmithKline, Novartis, Merck, and Pfizer.

Pertussis Vaccine Protection Wanes 42% Every Year

Medscape September 12, 2012

The odds of acquiring pertussis increase 42% every year after children receive the fifth dose of the diphtheria-tetanus-acellular pertussis (DTaP) vaccine, leading to increasing outbreaks of whooping cough in immunized children, according to a study published in the September 13 issue of the New England Journal of Medicine …

The study suggests that the acellular pertussis vaccine, which replaced the whole-cell vaccine in the 1990s, is associated with increasing numbers of pertussis outbreaks. Whole-cell vaccine fell into disfavor with rising concerns about its association with severe reactions such as convulsions (1 case per 1750 doses administered, according to a report by the Centers for Disease Control and Prevention [CDC]); rarely, acute encephalopathy (0 – 10.5 cases per 1 million doses administered, according to the CDC); and, some conclude, lasting brain damage.

“Our findings highlight the need to develop new pertussis-containing vaccines that will provide long-lasting immunity,” the authors write.

New Pertussis Vaccine Not on the Horizon “Anytime Soon”

However, such a vaccine is unlikely to turn up anytime soon, Michael Pichichero, MD, professor in pediatrics, University of Rochester Medical Center, New York, told Medscape Medical News. Dr. Pichichero was not involved with the study.

“I doubt we will see such products soon on the market, since I am aware of no human trials involving new products that are underway,” …

Dr. Pichichero, who said that in his experience, whole-cell vaccine can lead to significant reactions, held that low immunization levels might play the most important role in any pertussis outbreak. “I also note that the study was conducted in California, a state with a disproportionate share of the population of parents who refuse vaccines or construct their own vaccine schedule by requesting delays in vaccination,” Dr. Pichichero noted.

“Pertussis is controlled to a significant degree by herd immunity…. Due to the vaccine practices of too many parents in California and the well-intentioned but misguided cooperation by healthcare providers, it may also be that the California pertussis outbreaks are due in part also to the lack of sufficient herd immunity to provide population protection,” he concluded.

Kaiser Permanente, the institution employing the study authors, has grants or pending grants with GlaxoSmithKline, Sanofi Pasteur, Pfizer, Merck, and Novartis. One coauthor is a vaccine safety fellow with the CDC. Dr. Pichichero has led trials evaluating various DTaP products and combinations of DTaP vaccines with other vaccines, such as hepatitis B and polio. He has served as a consultant to Sanofi Pasteur, unrelated to DTaP. His institution has received funding from GlaxoSmithKline for vaccine studies unrelated to DTaP.